ContraFect Corp Company Profile (NASDAQ:CFRX)

About ContraFect Corp (NASDAQ:CFRX)

ContraFect Corp logo

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CFRX
  • CUSIP: N/A
  • Web: www.contrafect.com
Capitalization:
  • Market Cap: $54.15 million
  • Outstanding Shares: 41,656,000
Average Prices:
  • 50 Day Moving Avg: $1.59
  • 200 Day Moving Avg: $1.92
  • 52 Week Range: $1.20 - $3.40
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.63
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.32 per share
  • Price / Book: 4.06
Profitability:
  • EBIDTA: ($32,360,000.00)
  • Return on Equity: -171.11%
  • Return on Assets: -110.46%
Debt:
  • Current Ratio: 6.91%
  • Quick Ratio: 6.91%
Misc:
  • Average Volume: 46,681 shs.
  • Beta: -1.09
  • Short Ratio: 4.71
 

Frequently Asked Questions for ContraFect Corp (NASDAQ:CFRX)

What is ContraFect Corp's stock symbol?

ContraFect Corp trades on the NASDAQ under the ticker symbol "CFRX."

How were ContraFect Corp's earnings last quarter?

ContraFect Corp (NASDAQ:CFRX) posted its quarterly earnings results on Monday, May, 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.17) by $0.02. View ContraFect Corp's Earnings History.

Where is ContraFect Corp's stock going? Where will ContraFect Corp's stock price be in 2017?

3 equities research analysts have issued 1 year price objectives for ContraFect Corp's shares. Their forecasts range from $5.00 to $5.00. On average, they expect ContraFect Corp's stock price to reach $5.00 in the next year. View Analyst Ratings for ContraFect Corp.

Are investors shorting ContraFect Corp?

ContraFect Corp saw a increase in short interest during the month of April. As of April 28th, there was short interest totalling 198,356 shares, an increase of 11.0% from the April 13th total of 178,765 shares. Based on an average trading volume of 16,340 shares, the days-to-cover ratio is presently 12.1 days.

Who are some of ContraFect Corp's key competitors?

Who owns ContraFect Corp stock?

ContraFect Corp's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Broadfin Capital LLC (3.43%), Oracle Investment Management Inc. (2.84%), Vanguard Group Inc. (2.45%), Birchview Capital LP (1.74%), Sunbelt Securities Inc. (0.48%) and Westfield Capital Management Co. LP (0.36%). Company insiders that own ContraFect Corp stock include Daniel Couto and Steven C Gilman. View Institutional Ownership Trends for ContraFect Corp.

Who sold ContraFect Corp stock? Who is selling ContraFect Corp stock?

ContraFect Corp's stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc.. View Insider Buying and Selling for ContraFect Corp.

Who bought ContraFect Corp stock? Who is buying ContraFect Corp stock?

ContraFect Corp's stock was bought by a variety of institutional investors in the last quarter, including Westfield Capital Management Co. LP and Geode Capital Management LLC. View Insider Buying and Selling for ContraFect Corp.

How do I buy ContraFect Corp stock?

Shares of ContraFect Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of ContraFect Corp stock cost?

One share of ContraFect Corp stock can currently be purchased for approximately $1.30.

Analyst Ratings

Consensus Ratings for ContraFect Corp (NASDAQ:CFRX) (?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $5.00 (284.62% upside)

Analysts' Ratings History for ContraFect Corp (NASDAQ:CFRX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/19/2017Maxim GroupReiterated RatingHoldHighView Rating Details
11/21/2016Piper Jaffray CompaniesSet Price TargetBuy$5.00N/AView Rating Details
9/28/2016William BlairInitiated CoverageOutperformN/AView Rating Details
5/10/2016Roth CapitalDowngradeBuy -> Neutral$4.00 -> $3.30N/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for ContraFect Corp (NASDAQ:CFRX)
Earnings by Quarter for ContraFect Corp (NASDAQ:CFRX)
Earnings History by Quarter for ContraFect Corp (NASDAQ:CFRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($0.17)($0.15)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.20)$0.01ViewN/AView Earnings Details
11/9/2016Q3 2016($0.21)($0.28)ViewN/AView Earnings Details
8/9/2016Q216($0.27)($0.35)ViewN/AView Earnings Details
5/10/2016Q1 2016($0.25)($0.32)ViewN/AView Earnings Details
3/15/2016Q415($0.23)($0.28)ViewN/AView Earnings Details
8/13/2015Q2 2015($0.27)($0.33)ViewN/AView Earnings Details
5/15/2015Q1 2015($0.26)($0.24)ViewN/AView Earnings Details
4/6/2015Q4 2014($0.23)($0.23)ViewN/AView Earnings Details
11/14/2014Q3 2014($0.13)($1.22)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ContraFect Corp (NASDAQ:CFRX)
2017 EPS Consensus Estimate: ($0.68)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.16)($0.16)($0.16)
Q2 20172($0.17)($0.15)($0.16)
Q3 20172($0.18)($0.17)($0.18)
Q4 20172($0.18)($0.18)($0.18)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for ContraFect Corp (NASDAQ:CFRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for ContraFect Corp (NASDAQ:CFRX)
Insider Ownership Percentage: 15.00%
Institutional Ownership Percentage: 46.18%
Insider Trades by Quarter for ContraFect Corp (NASDAQ:CFRX)
Institutional Ownership by Quarter for ContraFect Corp (NASDAQ:CFRX)
Insider Trades by Quarter for ContraFect Corp (NASDAQ:CFRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/27/2016Steven C GilmanCEOBuy20,000$2.48$49,600.00View SEC Filing  
11/17/2015Daniel CoutoSVPSell2,872$3.81$10,942.32View SEC Filing  
11/3/2015Daniel CoutoSVPSell2,867$4.23$12,127.41View SEC Filing  
10/20/2015Daniel CoutoSVPSell2,867$4.48$12,844.16View SEC Filing  
10/6/2015Daniel CoutoSVPSell2,867$4.11$11,783.37View SEC Filing  
9/22/2015Daniel CoutoSVPSell2,867$4.76$13,646.92View SEC Filing  
9/8/2015Daniel CoutoSVPSell2,867$4.90$14,048.30View SEC Filing  
3/2/2015Julia P GregoryCEOBuy11,778$4.61$54,296.58View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for ContraFect Corp (NASDAQ:CFRX)
Latest Headlines for ContraFect Corp (NASDAQ:CFRX)
Source:
DateHeadline
americanbankingnews.com logoShort Interest in ContraFect Corp (CFRX) Grows By 11.0%
www.americanbankingnews.com - May 14 at 9:14 AM
americanbankingnews.com logoZacks Investment Research Analysts Lift Earnings Estimates for ContraFect Corp (CFRX)
www.americanbankingnews.com - May 12 at 1:18 PM
americanbankingnews.com logo Brokerages Expect ContraFect Corp (CFRX) to Announce -$0.16 Earnings Per Share
www.americanbankingnews.com - May 12 at 8:28 AM
americanbankingnews.com logoWilliam Blair Weighs in on ContraFect Corp's Q2 2017 Earnings (CFRX)
www.americanbankingnews.com - May 11 at 9:10 AM
finance.yahoo.com logoCFRX: Final Logistics Being Completed For Initiation of Phase 2 Trial of CF-301 in mid-2017
finance.yahoo.com - May 9 at 9:13 PM
americanbankingnews.com logoContraFect Corp (CFRX) Issues Earnings Results
www.americanbankingnews.com - May 9 at 12:12 PM
finance.yahoo.com logoContraFect Announces First Quarter 2017 Financial Results
finance.yahoo.com - May 8 at 10:07 AM
finance.yahoo.com logoContraFect reports 1Q loss
finance.yahoo.com - May 8 at 10:07 AM
americanbankingnews.com logoContraFect Corp (CFRX) Earning Favorable Media Coverage, Report Finds
www.americanbankingnews.com - May 4 at 1:11 AM
americanbankingnews.com logoContraFect Corp (CFRX) Getting Positive Press Coverage, Study Finds
www.americanbankingnews.com - April 26 at 4:26 PM
americanbankingnews.com logoContraFect Corp (CFRX) Earns Daily News Sentiment Score of 0.44
www.americanbankingnews.com - April 23 at 12:58 PM
americanbankingnews.com logoContraFect Corp (CFRX) Rating Reiterated by Maxim Group
www.americanbankingnews.com - April 22 at 10:14 PM
americanbankingnews.com logoContraFect Corp (CFRX) Earns Daily Coverage Optimism Score of 0.22
www.americanbankingnews.com - April 20 at 6:15 PM
finance.yahoo.com logoContraFect to Present New Data at the 27th European Congress of Clinical Microbiology and Infectious Disease (ECCMID)
finance.yahoo.com - April 19 at 12:55 PM
americanbankingnews.com logoZacks: ContraFect Corp (CFRX) Given $7.00 Consensus Target Price by Analysts
www.americanbankingnews.com - April 4 at 12:01 AM
americanbankingnews.com logoZacks Investment Research Research Analysts Increase Earnings Estimates for ContraFect Corp (CFRX)
www.americanbankingnews.com - March 22 at 10:05 AM
americanbankingnews.com logoContraFect Corp (CFRX) to Post Q1 2017 Earnings of ($0.16) Per Share, Zacks Investment Research Forecasts
www.americanbankingnews.com - March 21 at 9:19 AM
finance.yahoo.com logoCFRX: Phase 2 Trial of CF-301 to Initiate in mid-2017
finance.yahoo.com - March 20 at 2:42 PM
biz.yahoo.com logoCONTRAFECT CORP Files SEC form 10-K, Annual Report
biz.yahoo.com - March 15 at 9:37 PM
finance.yahoo.com logoContraFect Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
finance.yahoo.com - March 15 at 4:36 PM
finance.yahoo.com logoCORRECTION - ContraFect Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
finance.yahoo.com - March 15 at 4:36 PM
streetinsider.com logoContraFect's (CFRX) Chairman and Takes Temporary Medical Leave
www.streetinsider.com - March 14 at 9:09 PM
biz.yahoo.com logoCONTRAFECT CORP Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits
biz.yahoo.com - March 14 at 11:34 AM
us.rd.yahoo.com logoContraFect Chairman and CEO Steven C. Gilman Takes Temporary Medical Leave
us.rd.yahoo.com - March 13 at 12:44 PM
us.rd.yahoo.com logoLisa Ricciardi to Join Board of Directors
us.rd.yahoo.com - February 16 at 9:40 AM
finance.yahoo.com logoCONTRAFECT CORP Financials
finance.yahoo.com - February 8 at 4:33 PM
us.rd.yahoo.com logo7:02 am ContraFect reports investigational drug product lot did not meet manufacturing release specifications; now expects to initiate the Phase 2 study of CF-301 in Staph aureus in mid-2017
us.rd.yahoo.com - January 6 at 4:39 PM
finance.yahoo.com logoContraFect to Present at Biotech Showcase 2017 Conference
finance.yahoo.com - January 4 at 5:19 PM
finance.yahoo.com logoGreenwood Hall Announces Appointment of Rubinstein, Sucoff, and Poutre to Board of Directors
finance.yahoo.com - November 30 at 8:00 AM
finance.yahoo.com logoContraFect to Present at 28th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 23 at 1:10 PM
streetinsider.com logoContraFect (CFRX) Receives $2.1M PRMRP-Related Development Award
www.streetinsider.com - November 17 at 3:24 PM
finance.yahoo.com logoCFRX: Preparations Continue for Launch of Phase 2 Clinical Trial of CF-301 in 4Q16…
finance.yahoo.com - November 14 at 4:20 PM
finance.yahoo.com logoContraFect to Present at The Lysin Meeting
finance.yahoo.com - November 10 at 10:12 PM
finance.yahoo.com logoCFRX: CF-301 Phase 2 Study in Bacteremia to Initiate in 4Q16
finance.yahoo.com - August 11 at 4:16 PM
biz.yahoo.com logoCONTRAFECT CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
biz.yahoo.com - August 9 at 12:01 PM
biz.yahoo.com logoCONTRAFECT CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements an
biz.yahoo.com - July 27 at 9:31 AM
streetinsider.com logoContraFect (CFRX) Prices 14M Common Stock, Warrants Offering for Proceeds of ~$35M
www.streetinsider.com - July 22 at 4:12 PM
finance.yahoo.com logoCFRX: Company Raises $35 Million; Steven Gilman Appointed as CEO
finance.yahoo.com - July 22 at 2:20 PM
finance.yahoo.com logoContraFect downgraded by Maxim Group
finance.yahoo.com - July 22 at 11:51 AM
biz.yahoo.com logoCONTRAFECT CORP Files SEC form 8-K, Termination of a Material Definitive Agreement, Change in Directors or Principal
biz.yahoo.com - July 21 at 5:30 PM
finance.yahoo.com logoContraFect Corporation Names Steven C. Gilman, PhD Chief Executive Officer
finance.yahoo.com - July 21 at 5:29 PM
finance.yahoo.com logoCFRX: New PK/PD and Microbiologic Data Presented on CF-301
finance.yahoo.com - June 27 at 2:30 PM
biz.yahoo.com logoCONTRAFECT CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - June 27 at 6:10 AM
finance.yahoo.com logo7:01 am ContraFect announces 3 presentations of new data on CF-301 at ASM 2016
finance.yahoo.com - June 21 at 7:01 AM
biz.yahoo.com logoQ1 2016 ContraFect Corp Earnings Release - Time Not Supplied
biz.yahoo.com - May 10 at 7:07 AM
finance.yahoo.com logoCFRX: CF-301 Phase 1 Results Presented at ECCMID Conference
finance.yahoo.com - April 12 at 1:35 PM
biz.yahoo.com logoCONTRAFECT CORP Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - April 12 at 6:03 AM

Social

Chart

ContraFect Corp (CFRX) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff